PhD on Antibiotic Tolerance Across Bacterial Pathogens

PhD on Antibiotic Tolerance Across Bacterial Pathogens

Quick Decision

Why can bacteria survive antibiotic exposure without becoming conventionally resistant, and does the explanation transfer across species? This doctorate connects that biological question with population genomics and quantitative analysis. A coherent supervisor research programme, complementary co-supervision and the four-year MIBTP network support the opportunity; an achievable initial scope and access to the necessary resources still need agreement.

The saved official project names Carolin Kobras as primary supervisor, Michelle Buckner as secondary supervisor and the University of Birmingham as the registration institution. The saved listing gives October 2027 entry and a closing date of 23 November 2026. Birmingham covers international tuition for selected MIBTP awardees; selection remains competitive, with up to 30% of MIBTP awards in a cohort available to international students; whether that cohort covers the entire partnership remains unconfirmed. The first practical step is to use the exact project-linked application route and establish academic equivalence, rather than treating an expression of interest as an award. Official project, 2027 application and eligibility.

Research Problem and Doctoral Work

What remains unresolved

Tolerance and resistance describe different phenomena: an otherwise susceptible population may survive antibiotic exposure without the conventional increase in growth-based resistance. This distinction matters for interpreting persistent or recurrent infection. The project asks whether important human pathogens share tolerance-related patterns or rely on species-specific strategies, how those patterns change over evolutionary time, and how tolerance relates to antimicrobial resistance. Its scope includes ESKAPE and WHO-priority pathogens, extending an established staphylococcal programme.

The advertised work combines bacterial genetics, high-throughput phenotyping and experimental evolution with population genomics and machine learning, connecting laboratory discoveries with clinical isolate collections. These are broad research components, not a specified experimental protocol or a promise that every student will master every technique before entry. The balance between experimental and computational work, initial species coverage and milestones are not yet public.

Scientific value and limits

A useful conceptual challenge is whether findings from restricted laboratory contexts remain informative across naturally diverse bacterial populations. Statistical associations, biological interpretation and clinically meaningful prediction are different evidential steps. Kobras's 2026 review explicitly identifies unresolved clinical relevance as a field limitation. The advertised project could generate a comparative research thesis and reproducible analytical outputs; a clinical diagnostic or treatment is not a promised deliverable. Review and publication record.

WHO's 2024 priority-pathogen framework supports the wider importance of AMR research and investment. It does not establish that a tolerance measure is already clinically validated. This is a substantial infectious-disease and genomic-research question, with translational uncertainty that should be treated as part of the doctorate. WHO report.

School, Programme and Field Context

The registration institution is Birmingham, in the United Kingdom. The saved school recruitment list places this exact project in 865D PhD in Microbes, Infections and Microbiomes MIBTP, within the School of Infection, Inflammation and Immunology, College of Medicine and Health. This differs from the School of Biosciences attribution in the collected project introduction. Use the exact project-linked MIBTP route when applying and confirm its availability. IMI spans the Medical School and Biosciences buildings, which helps explain the institutional overlap without making the programme names interchangeable. Birmingham MIBTP list, IMI.

Birmingham's official summary gives 68th globally and 10th in the UK in QS World University Rankings 2027, an overall institutional measure. In REF 2021, Biological Sciences had 45% four-star and 48% three-star research; Clinical Medicine had 49% and 43%, respectively. These historical unit profiles provide relevant institutional context, not a microbiology league position or a ranking of this recently established laboratory. League tables, REF unit profiles.

MIBTP is a four-year cohort programme. Its FAQ describes three-month partner-university research, industry and technical placements alongside network training. The retained detailed timetable carries a 2025 heading, so its programming, statistics, modelling, communication and career activities are indicative rather than a confirmed 2027 calendar. The generic subject PhD lists a minimum 36-month full-time registration and annual progress reviews, culminating in a thesis and viva; that generic duration must not replace the MIBTP award period. Confirm the individual registration and funding letter. Oxford collaboration does not imply an Oxford degree or a joint award. MIBTP FAQ, dated training outline, subject PhD.

Supervisor and Lab Assessment

Kobras is a BBSRC Fellow and Assistant Professor in Bacterial Genomics. Her independent Birmingham group began in 2026, following research in Bath, Sheffield and Oxford. Recent work supports experience spanning microbial biology, genomic analysis and collaboration. A new independent group offers the possibility of close involvement in its development, but its completed Birmingham doctoral outcomes and current day-to-day staffing are not established by public evidence. Her separate research grant runs from January 2026 to December 2028; those dates do not define the four-year studentship. Staff profile, research portfolio.

Three recent contributions clarify the academic direction. They were assessed from institutional abstracts and bibliographic records; publisher redirects failed, so no full-text methods review is claimed.

Paper	Contribution relevant to this PhD	Limit on interpretation
Transforming antibiotic tolerance research through genomics, Genome Biology, 2026	Synthesises the move toward connecting tolerance research with genomic diversity and clinical questions. The article-specific record reports advance online publication on 2 October 2026.	A review; it identifies unresolved clinical relevance rather than demonstrating clinical efficacy.
GeneScanner: profiling genetic variation across bacterial populations, Microbial Genomics, 2 June 2026	Presents an accessible computational tool, supported by synthetic-data and three cross-species case studies; evidence of supervisor-led tool development.	Published demonstrations do not establish accuracy for this project's future datasets or diagnostic readiness.
Functional and comparative genomic characterization of biofilm formation in Staphylococcus aureus, Biofilm, June 2026; early online December 2025	Connects phenotype variation with comparative genomic analysis in a collaboration including Kobras.	Biofilm formation is distinct from tolerance, and this narrower study does not establish cross-pathogen clinical generalisation.

The corresponding records are review, GeneScanner and Biofilm paper. The supplied 2026 preprint was not independently authenticated and is not counted among these three assessed papers.

Buckner adds complementary experience in clinically relevant Gram-negative bacteria and antimicrobial resistance. The project also states a longstanding Ineos Oxford Institute collaboration. Institutionally, IMI describes computational genomics, experimental microbiology and clinical links, including University Hospitals Birmingham. Access to particular collections, computing allocations or facilities for this student is not confirmed simply by institutional capability. Buckner profile, IMI genomics environment.

Kobras's public supervision statement offers at least weekly face-to-face meetings, initially hands-on guidance and increasing independence. Some laboratory tasks follow a shared rota; feedback on writing up to 5,000 words requires two weeks' notice. The interview should establish the actual split between the two supervisors, experienced staff and Oxford collaborators.

Funding, Application, and Living Cost

International and mainland-China eligibility

MIBTP accepts international applicants and assesses overseas equivalent qualifications. Nothing in the saved Birmingham route excludes applicants educated and resident in mainland China. This establishes eligibility to compete, not eligibility of every individual degree or a likelihood of selection. The up-to-30% international award share is a cohort proportion, not this project's allocation or an individual applicant's probability; whether the cohort covers the entire partnership remains unconfirmed, and the project-specific award count is unconfirmed. For successful Birmingham awardees, UKRI pays the home-fee component and Birmingham covers the international difference.

Academic routes include a relevant first or high upper-second undergraduate degree; a lower upper-second plus a relevant Master's or at least three years' postgraduate experience may qualify, while lower grades generally need exceptional additional experience. The university's research policy permits assessed alternatives and does not make a Master's universally compulsory. The China country page's numeric grade table is labelled PGT/Master's and should not be reused as a confirmed doctoral cutoff. MIBTP eligibility, research entry policy, China guidance and table scope.

Financial coverage and budget

The retained UKRI reference is £21,805 annually for 2026/27, approximately £1,817 monthly. It is not a confirmed 2027/28 award. MIBTP also describes research consumables, travel/conference support and a laptop; these are different from unrestricted personal living income. UKRI explicitly excludes visa and immigration health surcharge costs. UKRI student support.

The university recommends 52-week postgraduate budgeting. Its essentials table, with accommodation based on 2025/26, supports the following arithmetic:

Scenario	Weekly essentials	52-week essentials	£21,805 less these essentials
Private house	£241–253	£12,532–13,156	£8,649–9,273
Self-catered halls	£268–280	£13,936–14,560	£7,245–7,869

Transport, socialising, dining out, clothing, arrival charges and later price changes are excluded; the residual is budget headroom, not predicted savings. Saved room-search examples span £147 weekly for an Ashcroft shared-bathroom room and £230–233 for a Battery Park ensuite, reinforcing the importance of room type and contract length. Neither page guarantees a 2027 room or price. Budget guidance, room examples.

Submission rules that matter

Apply through the specific Birmingham project-linked MIBTP programme, with the exact title and supervisor; email is not an application. Birmingham allows one project per programme and up to five programme applications, submitted separately. Provide English transcripts/certificates, CV and the research-methods training answer. A proposal is not required; the mandatory upload slot can take a blank document. The personal statement is optional, with N/A allowed in its mandatory box. Complete the separate EDI form and arrange references, including at least one academic referee. Birmingham-specific instructions govern where the central FAQ is broader.

The subject PhD lists IELTS 6.5 overall with no component below 6.0, or stated equivalents; confirm the condition on the exact MIBTP offer. Birmingham allows language evidence after initial application. The saved schedule anticipates shortlisting by late January and overseas Zoom interviews in early February 2027. The central FAQ still contains an October 2026 language example; the saved 2027 application pages identify the intake. Deadline clock time and reference-completion cut-off remain unconfirmed.

Applicant Fit and Preparation

The most coherent backgrounds combine microbiology, genetics or genomics with readiness for quantitative work. A computational bioscience applicant may also be well aligned if prepared to engage with biological interpretation and experimental research. Conversely, a strictly coding-only expectation or reluctance to undertake quantitative and cross-campus training would conflict with the advertised mode. These are assessments of research fit, not additional formal entry rules.

Useful preparation is to explain a previous research contribution, its limitations and the reasoning behind an analysis; demonstrate statistics, reproducible data handling and clear biological interpretation; and identify which side of the laboratory/computational interface needs further training. Neither machine-learning mastery nor a particular programming language is advertised as a universal entry condition. The applicant need not submit an unsolicited detailed experimental plan.

Career and transferable skills

The transferable value lies in microbiology research, genomic analysis and biotechnology skills. The UK's 2026 life-sciences indicators report pharmaceutical business R&D of £9.3 billion in 2024 and life-sciences equity investment of £4.5 billion, up from £3.4 billion in 2023. These describe a broad ecosystem, not AMR vacancies or graduate salaries. Clinical microbiology is a separate regulated route: NHS Scotland describes specialist pre-registration training and HCPC registration, so this PhD alone does not confer clinical-scientist status. Government indicators, NHS pathway.

Next Actions and Questions to Verify

Before applying, check the 865D project link and whether the topic remains available. If equivalence is unclear, send a concise eligibility enquiry with degree and transcript context. Confirm project availability, exact deadline time, reference timing and the MIBTP-specific language condition. Prepare the required documents before 23 November rather than waiting for optional supervisor contact.

At interview, ask how Kobras, Buckner and collaborators divide supervision; what initial scope is feasible; how laboratory and computational time will be balanced; which data permissions and resources are already secured; and how 2027 training and placements fit the research milestones. The question is whether the project has a supported, achievable doctorate-sized core.

Before accepting, obtain a letter confirming four years of support, full overseas tuition, the 2027/28 stipend and increases, research/travel coverage and payment timing. Check a realistic 52-week housing contract, personal visa/IHS and arrival costs, and who pays additional placement travel or accommodation. These checks resolve the remaining financial and practical uncertainty without treating an advertised project as a guaranteed award.

Evidence and Sources

Current vacancy availability and personal award eligibility remain unconfirmed. Paper assessments use the existing institutional abstracts and bibliographic metadata, not full-text methods reviews. The stated scope, resources and material unknowns remain qualified above.

Project, programme and eligibility

• S01 — Official Kobras project and supervision profile
• S02 — Birmingham MIBTP 2027 funding, project list and application
• S03 — MIBTP current application and eligibility
• S04 — MIBTP FAQ
• S05 — Dated MIBTP training outline
• S16 — Microbiology and Infection subject PhD
• S17 — University research entry policy
• S18 — China qualifications guidance

Supervisor, papers and research environment

• S06 — Kobras staff profile
• S07 — Kobras institutional research portfolio
• S08 — 2026 tolerance/genomics review
• 2026 tolerance/genomics review DOI
• Project-cited 2026 bioRxiv preprint DOI — not independently authenticated
• S09 — 2026 GeneScanner paper
• S10 — 2026 staphylococcal biofilm paper
• S11 — Buckner supervisor profile
• S12 — Birmingham league tables
• S13 — REF 2021 unit profiles
• S14 — Institute of Microbiology and Infection
• S15 — IMI genomics and microbiomes environment

Finance, field and careers

• S19 — UKRI funded-student support
• S20 — Official postgraduate budgeting guidance
• S21 — Birmingham room-search prices
• S22 — WHO 2024 priority-pathogen report
• S23 — UK life-sciences competitiveness indicators 2026
• S24 — NHS Scotland microbiology clinical-scientist pathway